Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked disorder caused by dystrophin deficiency, leading to progressive muscle degeneration.
• Current FDA-approved treatments for DMD include exon skipping using phosphorodiamidate morpholino oligomers (PMOs).
• Peptide-conjugated PMOs (PPMOs) enhance exon skipping efficacy, particularly in cardiac tissue, offering a promising therapeutic avenue for DMD.

Purpose of the Study:

• To develop and validate sensitive methodologies for quantifying PPMO uptake in the heart.
• To evaluate the efficacy of exon 51 skipping induced by PPMO administration in a humanized DMD mouse model.
• To compare the sensitivity of enzyme-linked immunosorbent assay (ELISA) with traditional methods like HPLC and LC/MS for PPMO detection.

Main Methods:

• Development of an enzyme-linked immunosorbent assay (ELISA) to determine PPMO uptake efficiency in cardiac tissue.
• Administration of PPMO via retro-orbital injection into a humanized DMD mouse model.
• Quantification of exon 51 skipping efficacy using reverse transcription polymerase chain reaction (RT-PCR).

Main Results:

• The developed ELISA method demonstrated high sensitivity for detecting PPMO uptake in the heart.
• RT-PCR analysis confirmed successful and measurable exon 51 skipping following PPMO administration.
• The study established reliable protocols for assessing PPMO therapeutic efficacy in a relevant DMD model.

Conclusions:

• Sensitive ELISA and RT-PCR methods can effectively evaluate PPMO cardiac uptake and exon skipping efficacy in DMD mouse models.
• These methodologies provide crucial tools for advancing PPMO-based therapies for Duchenne muscular dystrophy.
• Optimized detection methods are essential for the clinical translation of novel DMD treatments.